Warner-lambert Company

Jay Weiss

Nouman A Muhammad

Russell U Nesbitt

Michael Ray Harris

Gerard C Hokanson

Nancy L Mills

Wayne Boisvert

Gary D'Alonzo

Jane Ellen Daniel

Mahdi B Fawzi

Sadath U Khan

Phyllis Ying

Jatin J Shah

Pankaj B Gala

S Shirley Yang

Shirley Yang

The present invention is directed to ACE inhibitor-containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.

Stabilization of quinapril using magnesium oxide

An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.

Stable oral CI-981 formulation and process for preparing same

Stable oral CI-981 formulation and process of preparing same

The present invention pertains to a dual control sustained release drug delivery system which comprises a core and a porous coating layer over the core, wherein the coated core comprises (A) a core comprising in percentages by weight of the core composition (a) a medicament present in an amount from about 60% to about 90%; (b) an edible material having a melting point from about 25.degree. C. to about 100.degree. C. selected from the group consisting of (i) fatty acids having an iodine value from about 1 to about 10, (ii) natural waxes, (iii) synthetic waxes, and (iv) mixtures thereof, present in an amount from about 5% to about 40%; and (B) a porous coating layer over the core comprising in percentages by weight of the coating layer composition (a) a pH-independent water-insoluble polymer present in an amount from about 40% to about 80%; and (b) a water-soluble film forming polymer present in an amount from about 20% to about 60%.

Dual control sustained release drug delivery systems and methods for

A solid composition for peroral therapy of cognition impairment is formulated to stabilize the acid labile drug, CI-979 HCl, by layering a mixture of thereof with a binder on mini-sugar spheres, and finally covering the structure with a protective coating.

Composition for peroral therapy of cognition impairment and a process

The present invention pertains to controlled release tacrine drug delivery systems comprising an immediate release composition and a sustained release composition wherein (1) the immediate release composition comprises in percentages by weight of the immediate release composition: (A) immediate release pellets comprising: (a) nonpareil seeds in an amount from about 25% to about 75%; (b) tacrine in an amount from about 10% to about 80%; and (c) a binding agent in an amount from about 1% to about 10%; and (B) a sealing layer over the immediate release pellets comprising: (a) a sealing agent in an amount up to about 6%, and (b) a first plasticizing agent in an amount up to about 5%; and (2) the sustained release composition comprises in percentages by weight of the sustained release composition; (A) the immediate release composition; and (B) a sustaining layer over the immediate release composition comprising; (a) a water-insoluble polymer in an amount from about 40% to about 90%; (b) a water-soluble polymer in an amount up to about 10%; and (c) a second plasticizing agent in an amount up to about 10%; wherein the sustaining layer and the immediate release composition are present in the sustained release composition in a ratio by weight from about 1:9 to about 4:6, respectively, and the immediate release composition and the sustained release composition are present in the drug delivery system in a ratio by weight from about 0.01:1 to about 1:1, respectively.

Controlled release tacrine drug delivery systems and methods for

A novel process for the preparation of pharmaceutical compositions involving the stabilization of the active drug(s) through the reduction of residual alcohol present in a drug/carrier blend. The presence of residual alcohol in dried pharmaceutical compositions adversely affects many drugs which must be initially dissolved therein in order to achieve uniform distributions throughout the excipient carrier materials. Wherein not previously possible, its removal is achieved utilizing precise processing parameters in which water lost during the drying process is replenished during blending in a conventional solids processor.

Process for the preparation of substantially alcohol free pharmaceutical

Semi-enteric controlled release formulations are comprised of a biological active agent such as an antibiotic that is blended with a water-soluble bulking agent, the mix then coated onto an inert core. The coated active core is further coated with a mixture comprised of an acrylic copolymer, bulking agent and pH dependent food acid. These different coating components possess different solubility characteristics which result in a gradual release of the active in both the stomach and small intestine that provides an increased bioavailability of the active drug.

Sustained release formulations

The present invention pertains to semi-enteric drug delivery systems which comprise (a) an inert core, (b) a first coating layer over the core comprising a medicament, and (c) a second coating layer over the first coating layer comprising a mixture of methacrylic acid copolymer, type C, and povidone present in a ratio by weight of from about 2:1 to about 24:1, respectively.

Growing community of inventors

East Brunswick, NJ, United States of America

Jay Weiss